297 related articles for article (PubMed ID: 35950928)
1. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
2. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
Castro LR; Schittl J; Fischmeister R
Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
[TBL] [Abstract][Full Text] [Related]
3. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.
Mullershausen F; Friebe A; Feil R; Thompson WJ; Hofmann F; Koesling D
J Cell Biol; 2003 Mar; 160(5):719-27. PubMed ID: 12604588
[TBL] [Abstract][Full Text] [Related]
4. Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.
Kleppe R; Jonassen I; Døskeland SO; Selheim F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462984
[TBL] [Abstract][Full Text] [Related]
5. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
Peak TC; Richman A; Gur S; Yafi FA; Hellstrom WJ
Sex Med Rev; 2016 Jan; 4(1):74-84. PubMed ID: 27872007
[TBL] [Abstract][Full Text] [Related]
6. Preservation of nitric oxide-induced relaxation of porcine coronary artery: roles of the dimers of soluble guanylyl cyclase, phosphodiesterase type 5, and cGMP-dependent protein kinase.
Liu J; Chen Z; Ye L; Liu H; Dou D; Liu L; Yu X; Gao Y
Pflugers Arch; 2014 Oct; 466(10):1999-2008. PubMed ID: 24413911
[TBL] [Abstract][Full Text] [Related]
7. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions.
Wilson LS; Elbatarny HS; Crawley SW; Bennett BM; Maurice DH
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13650-5. PubMed ID: 18757735
[TBL] [Abstract][Full Text] [Related]
8. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes.
Geng Y; Zhou L; Thompson WJ; Lotz M
J Biol Chem; 1998 Oct; 273(42):27484-91. PubMed ID: 9765278
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition.
Dangel O; Mergia E; Karlisch K; Groneberg D; Koesling D; Friebe A
J Thromb Haemost; 2010 Jun; 8(6):1343-52. PubMed ID: 20149081
[TBL] [Abstract][Full Text] [Related]
10. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
Jensen BO; Kleppe R; Kopperud R; Nygaard G; Døskeland SO; Holmsen H; Selheim F
Platelets; 2011; 22(1):8-19. PubMed ID: 20958117
[TBL] [Abstract][Full Text] [Related]
11. Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G.
Artim DE; Kullmann FA; Daugherty SL; Wu HY; de Groat WC
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F333-40. PubMed ID: 19493964
[TBL] [Abstract][Full Text] [Related]
12. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.
Mullershausen F; Russwurm M; Koesling D; Friebe A
Mol Biol Cell; 2004 Sep; 15(9):4023-30. PubMed ID: 15240816
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
15. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
[TBL] [Abstract][Full Text] [Related]
16. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
18. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.
Shimizu-Albergine M; Rybalkin SD; Rybalkina IG; Feil R; Wolfsgruber W; Hofmann F; Beavo JA
J Neurosci; 2003 Jul; 23(16):6452-9. PubMed ID: 12878685
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the L-arginine-NO-cGMP pathway in spontaneously hypertensive rat platelets: the effects of pregnancy.
Ognibene DT; Moss MB; Matsuura C; Brunini TM; de Moura RS; Mendes-Ribeiro AC; Resende AC
Hypertens Res; 2010 Sep; 33(9):899-904. PubMed ID: 20555333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]